Meeting
2020 ASCO Virtual Scientific Program
Validation of MAF biomarker for response prediction to adjuvant bisphosphonates in 2 clinical trials: AZURE and NSABP-B34.
Authors
Alexander H. G. Paterson
Tom Baker Cancer Center, Calgary, AB, Canada
Alexander H. G. Paterson , Stewart J. Anderson , Roger Gomis , Joel Jean-Mairet@inbiomotion.com , Juan-Carlos Tercero , Peter Lucas , Eleftherios P. Mamounas
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Discussion Session
Session Title
Breast Cancer—Local/Regional/Adjuvant
Track
Breast Cancer
Sub Track
Biologic Correlates
Citation
J Clin Oncol 38: 2020 (suppl; abstr 513)
DOI
10.1200/JCO.2020.38.15_suppl.513
Abstract #
513
Poster Bd #
5
Abstract Disclosures
Similar Posters
Poster
2023 ASCO Breakthrough
Delayed versus immediate use of zoledronic acid for postmenopausal patients with ER/PR positive early breast cancer who are using adjuvant letrozole.
First Author: Mai Abdel Gelil
Poster
2023 ASCO Annual Meeting
Adjuvant everolimus in patients (Pts) with localized non-clear cell renal cell carcinoma (RCC): Subgroup analysis from the Everest trial (SWOG S0931).
First Author: Shuchi Gulati
Poster
2017 ASCO Annual Meeting
Microvessel density as a prognostic marker in high-risk renal cell carcinoma.
First Author: Sarah A. Weiss
Poster
2014 ASCO Annual Meeting
Comparison of the clinical treatment score with the adjuvant online score and the risk for recurrence score for estimating prognosis in early-stage high-risk breast cancer patients: A Hellenic Cooperative Oncology Group study.
First Author: Kyriaki Pliarchopoulou